Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT Disease.

Inclusion Criteria: * Age \> 18 years old * Patients who have given their free informed and signed consent * Patients affiliated to a social security scheme or similar * Patients monitored for clinically confirmed HHT and/or with molecular biology confirmation * Patient with an Epistaxis Severity Score (ESS) \> 4 Exclusion Criteria: * Pregnant woman or woman of child bearing potential * Woman who are breast feeding. * Patient who is protected adults under the terms of the law (French Public Health Code). * Participation in another interventional clinical trial which may interfere with the proposed trial * Active infection. * (AST, ALT \> 1,5 fold upper limit of normal (ULN) and/or Bilirubin \> 1,5 fold upper limit of normal (ULN). * Severe renal impairment * Presence of non-treated pulmonary arteriovenous malformations accessible to a treatment on CT scan within 5 years. * Patients with hemoptysis or hematuria within 12 weeks prior to inclusion. * Patients with active gastro-intestinal (GI) bleeding or GI ulcers within 12 months prior to inclusion. * Presence of cerebral arteriovenous malformation. * Patients who require full-dose therapeutic anticoagulation (e.g. vitamin K antagonist or heparin, dabigatran) or high dose antiplatelet therapy, , patients under anticoagulation with rivaroxaban, apixaban and epixaban. * Patients with P-glycoprotein (P-gp) substrates/inducers/inhibitors (e.g.: ketoconazole, erythromycin, cyclosporine, rifampicin, carbamazepine, phenytoin, and St. John's Wort). * Patients with known coronary artery disease or recent history of myocardial infarction (within 1 year). * Known inherited predisposition to thrombosis or thrombotic events( including stroke and transient ischemic attack, excluded superficial venous thrombosis) within 12 months prior to inclusion. * Patients with QTc prolongation * Hypersensitivity to nintedanib, peanut or soya, or to any of the excipients. * Patient who incompletely filled in epistaxis grids within 8 weeks prior to inclusion. * Patient who have received intravenous bevacizumab within 6 months prior to inclusion. * Patient who had surgery (including ENT (Ear, Nose and Throat Specialist) surgery) within 12 weeks prior to inclusion. * Unhealed wound. * Planned major surgery within the next 3 months, including liver transplantation, major abdominal or intestinal surgery.